中国临床药理学杂志2016，Vol.32Issue(1)：6-8,3.DOI:10.13699/j.cnki.1001-6821.2016.01.002
来氟米特与泼尼松对免疫球蛋白A肾病的临床疗效与安全性研究
Clinical efficacy and safety for leflunomide and dehydrocortisone in the treatment of immunoglobulin A nephropathy
沈世忠 1杨忠民 1蔡佳盈 1谢潜红 1胡义阳 1孙凌云 1姜宗培2
作者信息
- 1. 福建医科大学 附属泉州第一医院 肾内科,福建泉州 362000
- 2. 中山大学附属第六医院肾内科,广州 510655
- 折叠
摘要
Abstract
Objective To evaluate the clinical efficacy and safety be-tween leflunomide and dehydrocortisone in the treatment of immunoglobu-lin A ( IgA) nephropathy.Methods Sixty IgA nephropathy patients were divided into control group (n=32) and experiment group(n=28). Patients in control group were administered metacortandracin 0.5 mg· kg-1 until 2 months.And then with 5 mg decrease every 2 weeks. Patients in experiment group were administered leflunomide 20 mg, twice a day for 3 days and than 20 mg, once a day for 3 months.The 24 h urine protein, glomerular filtration rate, albumin, clinical efficacy and safety were compared between the two groups .Results After treatment, the effective rate were 53.13% and 64.29% in control and experiment group, with no statistical difference (P>0.05).The 24 h urine protein was significantly decreased ( P<0.05 ) , glomerular filtration rate and al-bumin significantly increased in two groups after treatment ( P<0.05 ) , but there was no statistical difference between the two group ( P>0.05 ) . The incidence rate of adverse drug reaction in experiment group and con-trol group were 21 .43% and 15.63%, without significant difference (P>0.05).Conclusion Leflunomide was effective and safe in the treatment of IgA nephropathy , without difference with dehydrocortisone .关键词
免疫球蛋白A肾病/来氟米特/糖皮质激素/蛋白尿Key words
immunoglobulin A nephropathy/leflunomide/dehydrocorti-sone/albuminuria分类
医药卫生引用本文复制引用
沈世忠,杨忠民,蔡佳盈,谢潜红,胡义阳,孙凌云,姜宗培..来氟米特与泼尼松对免疫球蛋白A肾病的临床疗效与安全性研究[J].中国临床药理学杂志,2016,32(1):6-8,3.
